There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...

A scientist surrounded by vials and beakers in a modern laboratory, proudly displaying a vaccine. Moderna, Inc. (NASDAQ:MRNA) is a biotech company that develops vaccines based on messenger RNA (mRNA).

four years of the Biden administration’s failed oversight have made it necessary to review agreements for vaccine production,” an HHS spokesperson told Fierce Biotech in an email. A Moderna ...

Citi initiated coverage of Moderna (MRNA) with a Neutral rating and $40 price target Healthcare policy remains a key biopharma sector ...

Want to stay on top of the science and politics driving biotech ... subleasing its lab space. The Trump administration is reconsidering a $600 million BARDA contract with Moderna to develop ...

And the biotech says it's on track to deliver as many as 10 product approvals by 2027. If Moderna even makes it part of the way to that goal, it could be transformational for the company's ...

Why Moderna, Inc. (MRNA) Went Up On Tuesday? A scientist surrounded by vials and beakers in a modern laboratory ... Bancel's company, called Boston Biotech Ventures, bought 102,821 shares for ...

My name is Gina Wen. I’m a SMICCAL biotech analyst at Barclays. Welcome to our twenty seventh Global Healthcare Conference. On stage with me, we have two senior leadership from Moderna. We have Rose ...

The R.I. Life Science Hub is leading development of our state’s first life science incubator, and is already generating a great return on our investment, writes House Speaker K. Joseph Shekarchi ...

Cambridge-based Moderna played a crucial role in that ... The belt-tightening has stalled leasing of lab space in biotech centers from Kendall Square to Boston’s Seaport District, where the ...